Ratings Betta Pharmaceuticals Co., Ltd.

Equities

300558

CNE100002DD9

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-09 pm EDT			5-day change	1st Jan Change
42.84 ^CNY	-3.08%		+2.66%	-16.90%

Apr. 19	Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Jan. 04	C4 Therapeutics, Inc. announced that it has received $24.999997 million in funding from Betta Pharmaceuticals Co., Ltd.	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The company returns high margins, thereby supporting business profitability.

Weaknesses

The group shows a rather high level of debt in proportion to its EBITDA.
With an expected P/E ratio at 38.25 and 29.92 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The company's "enterprise value to sales" ratio is among the highest in the world.
The company appears highly valued given the size of its balance sheet.
The company is not the most generous with respect to shareholders' compensation.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
Over the past four months, analysts' average price target has been revised downwards significantly.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
BETTA PHARMACEUTICALS CO., LTD.	-16.90%	2.48B		C-
MERCK KGAA	+7.91%	72.81B		A
KYOWA KIRIN CO. LTD.	+12.64%	9.13B		A-
SK BIOPHARMACEUTICALS CO., LTD.	-10.56%	5.13B		A-
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+58.79%	4.99B		-
YUHAN CORPORATION	+4.07%	3.9B		B-
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-26.13%	2.32B		-
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+19.31%	2.17B	-	-
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B	-	-
SUPERNUS PHARMACEUTICALS, INC.	+0.07%	1.59B		D+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes